The present disclosure is directed to 2,6-diamino-pyrimidin-5-yl-carboxamide derivatives of formula (I) and tautomers thereof or pharmaceutically acceptable salts thereof which are inhibitors of Spleen tryosine kinase (syk) or Janus kinase (JAK). The disclosure is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions such as undesired thrombosis and Non Hodgkins Lymphoma which are mediated at least in part by syk kinase or JAK kinase activity. These compounds are used in the preparation of a medicament for inhibiting syk or JAK kinase or a signal transduction pathway mediated at least in part by syk kinase activity, wherein the medicament is suitable for treating a condition or disorder selected from the group consisting of cardiovascular disease, inflammatory disease and autoimmune disease and cell proliferative disorder.
